Lung Cancer/X
Jun 9, 2025, 19:08
Oncogene Cancer Research Shares MSK Study on Pre-Surgery Osimertinib in EGFR Lung Cancer
Oncogene Cancer Research — shared on X:
“How do we create better surgical outcomes for early stage EGFR lung cancer as neoadjuvant immuno is not indicated?
MSK Cancer Center shared pre‑surgery osimertinib (w or w/o chemo) led to major tumour shrinkage in EGFR lung cancer at ASCO.”
Oncogene Cancer Research referenced new findings from Memorial Sloan Kettering Cancer Center presented at ASCO, showing that pre-surgery osimertinib—with or without chemotherapy—led to significant tumor shrinkage in early-stage EGFR lung cancer where neoadjuvant immunotherapy is not indicated.
Find More Posts Featuring EGFR lung cancer on OncoDaily
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 9, 2025, 18:29
Jun 9, 2025, 18:21
Jun 9, 2025, 18:16
Jun 9, 2025, 18:14